Alkermes plc (ALKS) Q4 2025 Earnings Call Transcript
Access earnings results, analyst expectations, report, slides, earnings call, and transcript.
Overview
The earnings call highlights raised financial guidance, promising product development, and strategic acquisitions, all of which are positive indicators. Although management avoided some specifics, the overall tone and strategic direction suggest optimism. The market cap suggests moderate sensitivity, so a positive sentiment is anticipated.
Key Financial Performance
Total Revenues $1.5 billion in 2025, a 9% year-over-year growth driven by proprietary product portfolio.
VIVITROL Net Sales $467.9 million in 2025, a 2% year-over-year growth driven by growth in the alcohol dependence market and localized market dynamics.
ARISTADA Net Sales $370 million in 2025, a 7% year-over-year growth due to expanded prescriber breadth and strong new-to-brand prescriptions.
LYBALVI Net Sales $346.7 million in 2025, a 24% year-over-year growth driven by sustained momentum in new patient starts and improved payer access.
Manufacturing and Royalty Revenues $291.3 million in 2025, including $130.5 million from VUMERITY and $109.6 million from long-acting INVEGA products.
Cost of Goods Sold $196.5 million in 2025, down from $245.3 million in 2024, reflecting efficiencies from the sale of the Athlone-based manufacturing business.
R&D Expenses $324 million in 2025, up from $245.3 million in 2024, due to investments in Vibrance Phase II studies and orexin 2 receptor agonist candidates.
SG&A Expenses $701.5 million in 2025, up from $645.2 million in 2024, reflecting psychiatry field expansion, promotional activities, and legal/transaction-related expenses.
GAAP Net Income $241.7 million in 2025, reflecting strong profitability.
EBITDA $285.6 million in 2025, with adjusted EBITDA at $394 million, reflecting strong operational performance.
Cash and Investments $1.3 billion at the end of 2025, used $775 million for Avadel acquisition and entered into $1.525 billion term loans.
You have reached the limit. Sign up to access full content
Get started
Operating Highlights
Alixorexton: Planned to enter Phase III in narcolepsy this quarter after a rigorous Phase II program. Received FDA breakthrough therapy designation. Believed to have blockbuster potential and could advance the standard of care in central disorders of hypersomnolence.
LUMRYZ: A once-at-bedtime sodium oxybate for narcolepsy treatment. Generated $279 million in net sales in 2025 with 3,500 patients on therapy. Expected to generate $350-$370 million in 2026.
Avadel Acquisition: Acquisition completed, adding a new revenue stream and accelerating entry into the commercial sleep medicine market. Strengthens commercial platform for potential launches.
Revenue Growth: Generated $1.5 billion in 2025, with proprietary product portfolio growing 9% year-over-year. Expected 2026 revenue of $1.73-$1.84 billion.
Cost Management: Cost of goods sold decreased to $196.5 million in 2025 from $245.3 million in 2024 due to operational efficiencies.
Orexin Portfolio Expansion: Advancing ALKS 7290 for ADHD and ALKS 4510 for fatigue in neurodegenerative disorders. Both are progressing to Phase II trials in 2026.
You have reached the limit. Sign up to access full content
Get started
Risk or Challenges
Regulatory Hurdles: The company faces regulatory challenges, including the need for FDA approval for its Phase III programs and potential sNDA submission for LUMRYZ in idiopathic hypersomnia. These processes are critical for product launches and market entry.
Debt and Financial Obligations: The acquisition of Avadel required significant financial resources, including $775 million in cash and $1.525 billion in term loans. This debt could impact cash flow and financial flexibility, despite plans for rapid repayment.
Supply Chain and Cost Management: The cost of goods sold is expected to increase significantly in 2026 due to the inventory fair value step-up related to LUMRYZ, which could pressure margins.
Market Competition: The company operates in highly competitive markets, including psychiatry, sleep medicine, and ADHD, where it faces pressure from existing and new entrants.
Product Development Risks: The success of the company's growth strategy heavily depends on the clinical and commercial success of its orexin portfolio, including alixorexton and other candidates. Delays or failures in clinical trials could adversely impact strategic objectives.
Expiration of Royalties: The scheduled expiration of certain XEPLION royalties in the second half of 2026 will reduce manufacturing and royalty revenues, impacting overall financial performance.
Integration Challenges: The integration of Avadel's commercial team and operations poses risks, including potential disruptions and inefficiencies during the transition period.
You have reached the limit. Sign up to access full content
Get started
Guidance & Outlook
Revenue Expectations for 2026: Total revenues are expected to be in the range of $1.73 billion to $1.84 billion, driven primarily by net sales from proprietary products in the range of $1.52 billion to $1.6 billion.
Adjusted EBITDA for 2026: Expected to be in the range of $370 million to $410 million.
Proprietary Product Sales: Net sales expected to be $1.52 billion to $1.6 billion in 2026.
LUMRYZ Revenue: Expected total revenue in the range of $350 million to $370 million for 2026.
R&D Expenses for 2026: Expected to be in the range of $445 million to $485 million, reflecting increased investment in orexin portfolio and other development programs.
SG&A Expenses for 2026: Expected to be in the range of $890 million to $930 million, including $50 million of transaction costs related to the Avadel acquisition.
Net Interest Expense for 2026: Expected to be in the range of $75 million to $85 million.
Net Tax Benefit for 2026: Expected to be approximately $20 million.
GAAP Net Loss for 2026: Expected to be in the range of $115 million to $135 million, reflecting accounting related to the Avadel acquisition.
Phase III Brilliance Program for Alixorexton: Planned to initiate in Q1 2026, consisting of three 12-week randomized, placebo-controlled studies for narcolepsy types 1 and 2.
LUMRYZ Phase III Study in Idiopathic Hypersomnia: Data expected in Q2 2026, with potential sNDA submission and launch in early 2028 if approved.
ALKS 7290 Development for ADHD: Phase Ib study expected to begin in 2026, with data anticipated in the second half of the year. Phase II study planned for the second half of 2026.
ALKS 4510 Development for Fatigue in Neurodegenerative Disorders: Phase IIa study planned for 2026, targeting fatigue associated with multiple sclerosis and Parkinson's disease.
You have reached the limit. Sign up to access full content
Get started
Shareholder Return Plan
The selected topic was not discussed during the call.
You have reached the limit. Sign up to access full content
Get started
Key Q&A
Q:How should we think about the AE profile associated with split dosing in the Phase III trial?
A:The data so far for orexin 2 receptor agonists in treating narcolepsy show they are generally well-tolerated and safe. The split doses are modeled to drive later hours of wakefulness with a similar AE profile, minimizing side effects while maximizing efficacy.
Q:Can you speak about the potential synergies across the sales force after the Avadel deal closure?
A:There is not much overlap between the psychiatry and sleep medicine sales forces, allowing the psychiatry team to focus on LYBALVI and ARISTADA. Synergies are expected when launching alixorexton, with plans to build out the sales force to maximize opportunities for both LUMRYZ and alixorexton.
Q:What evidence would you need to convince payers to reimburse for both oxybate and orexin agonists?
A:Orexin agonists work on wakefulness, which may suffice for many patients. However, some patients benefit from oxybates for fragmented sleep. The company plans to generate data to explain to payers why both medicines might be effective for certain patients.
Q:What is your internal bar for ESS in the LUMRYZ Phase III in IH?
A:The IH study mirrors the previous oxybate program approved by the FDA. The primary endpoint is ESS, and key secondaries include PGIC and IHSS. The eligible population in the U.S. is estimated at 40,000, with low market penetration currently.
Q:Have you discussed key factors for a Phase III trial in IH with the FDA?
A:The company plans to follow the same process as for narcolepsy: obtaining Phase II data, holding an end-of-Phase II meeting with the FDA, and agreeing on the Phase III program. They will wait for Vibrance-3 data before initiating the meeting.
Q:What are your plans to study alixorexton along with an oxybate?
A:There is potential benefit for certain patients in using both alixorexton and oxybate. The company plans to generate evidence for reimbursement purposes rather than pursuing a registrational pathway. Investigators have shown interest in testing both agents together.
Q:How are you thinking about the field force for LUMRYZ, considering another market entrant by year-end?
A:The sales force is currently rightsized to target oxybate prescribers. Investments in the sales force and patient services have shown benefits. The company will monitor competitive entrants but believes LUMRYZ is uniquely positioned as the only once-nightly oxybate.
Q:How should we think about SG&A spend beyond 2026?
A:2026 SG&A includes $50 million in one-time transaction costs and commercial investments for LUMRYZ. Beyond 2026, the company plans to control spending, identify synergies, and reallocate costs as needed for evolving business needs.
Q:How are you thinking about the impact of first-generation full generic market formation on LUMRYZ?
A:The company believes LUMRYZ has a significant advantage as the only once-nightly oxybate. Payer access is strong, with over 90% of commercial patients having access. The company will monitor market dynamics but does not expect material changes in the short term.
Q:What is the development plan for valiloxybate, and could it replace LUMRYZ?
A:Valiloxybate is being developed for the low-to-no sodium space. The company is advancing the program rapidly, leveraging formulation capabilities. It is too early to determine if it will replace LUMRYZ or be an addition to the portfolio.
Q:Can you share details about your ADHD study?
A:The study will not enrich for specific ADHD phenotypes. Preclinical data suggest orexin agonists may have efficacy across ADHD domains. The company aims to discern dose response and efficacy signals in a short period.
Q:What is the protocol for split dosing in the alixorexton program?
A:The split dose aims to extend wakefulness into the evening while minimizing side effects. The company has modeled the timing and dosing based on Phase II data but has not disclosed specific details.
Q:How are you thinking about the timing of your decision to step down as CEO?
A:The decision was made because the company is in a strong position, having transformed into a proprietary products company with a potential blockbuster drug. The transition is logical, with Blair Jackson taking over.
Q:Will the Phase III design for NT1 and NT2 include split dosing?
A:Yes, the Phase III design will include split dosing for NT1 and NT2. The decision was made based on feedback from clinicians and Phase II data showing benefits for patients wanting extended wakefulness.
Q:What learnings can you take from Takeda's potential launch of oveporexton?
A:The company is particularly interested in Takeda's pricing strategy, which will set the tone for the market's receptivity to NT1 drugs. The positioning of oveporexton will also be monitored.
Q:What are your thoughts on the generic entry for VIVITROL in 2027?
A:The company plans to grow VIVITROL through 2026 and is preparing for multiple scenarios in 2027. Manufacturing and commercialization of generics are challenging, and the company is ready to compete or adjust spending as needed.
Q:When can we expect more detailed data on NT2?
A:Detailed NT2 data has been submitted for presentation at SLEEP in Baltimore in June. The company aims to provide more insights into the quality of efficacy in the NT2 population.
Q:What is the benchmark for 7290 in ADHD, and how does it compare to stimulants?
A:Preclinical data suggest orexin agonists may have efficacy comparable to stimulants in ADHD. The company is exploring the unique effects of orexin agonists on attention, focus, and vigilance.
Q:Review of Unclear Management Responses
A:Management avoided providing specific details on the protocol for split dosing in the alixorexton program, citing proprietary information. Additionally, they did not clarify the exact development plan for valiloxybate, stating it depends on early data. They also did not provide a clear benchmark for 7290 in ADHD compared to stimulants, emphasizing the need for clinical data.
You have reached the limit. Sign up to access full content
Get started
Earnings Word Cloud
The most frequently occurring keywords in this quarter's earning call
ADHD
ALKS Phase
Alkermes
Brilliance
II program
II study
III program
LUMRYZ bedtime
LUMRYZ inventory
LUMRYZ opportunity
LUMRYZ sale
MS Parkinson
Phase II
Phase III
RD activity
accounting
adult
alixorexton narcolepsy
breadth
breakthrough therapy
candidate
cash flow
closing acquisition
completion
dose cohort
element
fatigue
integration
month
option
orexin portfolio
payer
platform
prescriber
priority
sleep medicine
sodium
transaction
ALKS Transcript
Alkermes plc (ALKS) Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026 Transcript
Neutral6-10
Alkermes plc (ALKS) Q1 2026 Earnings Call Transcript
Positive5-5
The earnings call summary highlights strong financial performance with a 10% revenue increase, improved gross margins, and higher net income and EPS compared to the previous year. These positive financial metrics suggest a favorable market reaction. However, the absence of discussions on strategic initiatives, risks, and shareholder returns in the call limits a stronger sentiment rating. Given the company's market cap, the overall sentiment is positive, likely leading to a stock price increase of 2% to 8%.
Alkermes plc (ALKS) Q4 2025 Earnings Call Transcript
Positive2-25
The earnings call highlights raised financial guidance, promising product development, and strategic acquisitions, all of which are positive indicators. Although management avoided some specifics, the overall tone and strategic direction suggest optimism. The market cap suggests moderate sensitivity, so a positive sentiment is anticipated.
Alkermes plc (ALKS) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript
Neutral1-13
ALKS Report
Frequently Asked Questions
Where does this earnings call transcript come from?
All transcripts are sourced directly from the official live webcast or the company’s official investor relations website. We use the exact words spoken during the call with no paraphrasing of the core discussion.
How soon is the transcript available after the earnings call ends?
Full verbatim transcripts are typically published within 4–12 hours after the call ends. Same-day availability is guaranteed for all S&P 500 and most mid-cap companies.
Is the transcript edited or altered in any way?
No material content is ever changed or summarized in the “Full Transcript” section. We only correct obvious spoken typos (e.g., “um”, “ah”, repeated 10 times”, or clear misspoken ticker symbols) and add speaker names/titles for readability. Every substantive sentence remains 100% as spoken.
Why do some answers appear as “Unclear” or “Inaudible”?
When audio quality is poor or multiple speakers talk over each other, we mark the section instead of guessing. This ensures complete accuracy rather than introducing potential errors.
Who creates the AI Summary and Key Q&A highlights shown above the transcript?
They are generated by a specialized financial-language model trained exclusively on 15+ years of earnings transcripts. The model extracts financial figures, guidance, and tone with 97%+ accuracy and is regularly validated against human analysts. The full raw transcript always remains available for verification.
